CN117940130A - 用于脑癌治疗的贝伐拉非尼 - Google Patents

用于脑癌治疗的贝伐拉非尼 Download PDF

Info

Publication number
CN117940130A
CN117940130A CN202280019974.7A CN202280019974A CN117940130A CN 117940130 A CN117940130 A CN 117940130A CN 202280019974 A CN202280019974 A CN 202280019974A CN 117940130 A CN117940130 A CN 117940130A
Authority
CN
China
Prior art keywords
mutation
cancer
carrying
nras
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280019974.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·阿达姆凯维奇
M·J·道尔顿
S·马利克
P·托马斯
J·恩王
颜宜彬
金永勋
安永吉
金惟软
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hanmi Pharmaceutical Co Ltd
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Hanmi Pharmaceutical Co Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Hanmi Pharmaceutical Co Ltd, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CN117940130A publication Critical patent/CN117940130A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280019974.7A 2021-03-09 2022-03-08 用于脑癌治疗的贝伐拉非尼 Pending CN117940130A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163158798P 2021-03-09 2021-03-09
US63/158,798 2021-03-09
PCT/US2022/019273 WO2022192202A1 (en) 2021-03-09 2022-03-08 Belvarafenib for use in treatment of brain cancers

Publications (1)

Publication Number Publication Date
CN117940130A true CN117940130A (zh) 2024-04-26

Family

ID=80952247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280019974.7A Pending CN117940130A (zh) 2021-03-09 2022-03-08 用于脑癌治疗的贝伐拉非尼

Country Status (7)

Country Link
US (1) US20240173329A1 (https=)
EP (1) EP4304592A1 (https=)
JP (1) JP2024509269A (https=)
KR (1) KR20230156731A (https=)
CN (1) CN117940130A (https=)
TW (1) TW202300151A (https=)
WO (1) WO2022192202A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
BR112014015720B1 (pt) 2011-12-30 2020-03-17 Hanmi Pharm. Co., Ltd. Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
EP3624896A4 (en) * 2017-05-16 2021-03-31 Biomed Valley Discoveries, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
IL274969B2 (en) * 2017-11-30 2026-03-01 Hanmi Pharmaceutical Co Ltd Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[2,3-D]pyrimidine-7-carboxamide, and crystalline forms thereof
EP3560516A1 (en) * 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CA3178927A1 (en) * 2020-05-26 2021-12-02 Hanmi Pharm. Co., Ltd. Belvarafenib for use in cancer treatment

Also Published As

Publication number Publication date
KR20230156731A (ko) 2023-11-14
US20240173329A1 (en) 2024-05-30
WO2022192202A1 (en) 2022-09-15
JP2024509269A (ja) 2024-02-29
EP4304592A1 (en) 2024-01-17
TW202300151A (zh) 2023-01-01

Similar Documents

Publication Publication Date Title
JP7520189B2 (ja) 組み合わせ療法
AU2022291429B2 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
CN103153292B (zh) 联合抗癌疗法的组合物
WO2016160102A1 (en) Active metabolites of apilimod and uses thereof
US10821114B2 (en) Derivatives of cephalosporin for treating cancer
CN112533610A (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
EP2571358B1 (en) Combination therapy for treating cancer
CN117940130A (zh) 用于脑癌治疗的贝伐拉非尼
JP2022507686A (ja) 薬学的方法
HK40108904A (zh) 用於脑癌治疗的贝伐拉非尼
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
EP4731792A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108904

Country of ref document: HK